MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$6,786K
Free Cash flow
-$30,596K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from maturities of mark...
Share-based compensation expense
Investment tax credit receivable
Others
Negative Cash Flow Breakdown
Purchases of marketable securiti...
Net loss
Accrued expenses and other curre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-04-30
2026-01-31
2025-10-31
2025-07-31
Net loss
-30,227
-29,752
-37,880
-79,422
Non-cash interest expense
136
183
209
645
Loss on extinguishment of debt
0
-488
-
-
Loss on impairment of assets
147
-
-
-
Non-cash lease expense
-243
-246
-253
-125
Net amortization of premiums (accretion of discounts) on marketable securities
-
-
-3,067
-
Accretion of marketable securities
494
-2,054
-
2,645
Unrealized foreign currency losses
29
-69
25
-28
Share-based compensation expense
4,145
2,803
2,606
7,040
Depreciation of property and equipment
180
189
171
338
Investment tax credit receivable
-375
271
217
378
Prepaid expenses and other assets
1,582
2,422
-1,986
-3
Accounts payable
-625
-4,270
3,972
970
Accrued expenses and other current liabilities
-2,485
4,386
4,154
-1,024
Lease liabilities
-282
39
231
43
Net cash used in operating activities
-30,498
-28,903
-24,962
-74,277
Purchases of property and equipment
98
153
437
1,048
Purchases of marketable securities
50,214
169,187
7,748
153,095
Proceeds from maturities of marketable securities
73,950
43,043
48,685
88,505
Net cash used in investing activities
23,638
-126,297
40,500
-65,638
Proceeds from second amended term loan
0
25,000
-
-
Repayment of amended term loan principal
0
23,053
0
699
Payment of issuance costs associated with second amended term loan
-70
615
-
-
Proceeds from issuance of pre-funded warrants
1
23,249
-
-
Proceeds from public offering
0
126,250
-
-
Payment of issuance cost associated with public offering and pre-funded warrants
0
9,448
-
-
Proceeds from exercise of stock options
3
277
1,991
232
Net cash provided by financing activities
74
141,660
1,991
-467
Effect of exchange rate changes on cash and cash equivalents
0
1
0
1
Net decrease in cash and cash equivalents
-6,786
-13,539
17,529
-140,381
Cash and cash equivalents at beginning of period
36,613
50,152
173,004
-
Cash and cash equivalents at end of period
29,827
36,613
50,152
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from maturities
of marketable...
$73,950K
Payment of issuance
costs associated with...
-$70K
Proceeds from exercise of
stock options
$3K
Proceeds from issuance of
pre-funded warrants
$1K
Net cash used in
investing activities
$23,638K
Net cash provided by
financing activities
$74K
Canceled cashflow
$50,312K
Net decrease in cash
and cash...
-$6,786K
Canceled cashflow
$23,712K
Share-based compensation
expense
$4,145K
Investment tax credit
receivable
-$375K
Non-cash lease expense
-$243K
Depreciation of property and
equipment
$180K
Loss on impairment of
assets
$147K
Non-cash interest
expense
$136K
Purchases of marketable
securities
$50,214K
Purchases of property and
equipment
$98K
Net cash used in
operating activities
-$30,498K
Canceled cashflow
$5,226K
Net loss
-$30,227K
Accrued expenses and
other current...
-$2,485K
Prepaid expenses and
other assets
$1,582K
Accounts payable
-$625K
Accretion of marketable
securities
$494K
Lease liabilities
-$282K
Unrealized foreign
currency losses
$29K
Buy us a coffee
enGene Therapeutics Inc. (ENGN)
enGene Therapeutics Inc. (ENGN)